These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19959411)

  • 1. Raltegravir: molecular basis of its mechanism of action.
    Mouscadet JF; Tchertanov L
    Eur J Med Res; 2009 Nov; 14 Suppl 3(Suppl 3):5-16. PubMed ID: 19959411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging pharmacology: inhibitors of human immunodeficiency virus integration.
    Hazuda D; Iwamoto M; Wenning L
    Annu Rev Pharmacol Toxicol; 2009; 49():377-94. PubMed ID: 18928385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of HIV infection with raltegravir.
    Chirch LM; Morrison S; Steigbigel RT
    Expert Opin Pharmacother; 2009 May; 10(7):1203-11. PubMed ID: 19385721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Raltegravir: the first HIV integrase inhibitor. Introduction].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():1-2. PubMed ID: 19572418
    [No Abstract]   [Full Text] [Related]  

  • 6. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir.
    Sedaghat AR; Siliciano RF; Wilke CO
    Antivir Ther; 2009; 14(2):263-71. PubMed ID: 19430101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.
    Croxtall JD; Keam SJ
    Drugs; 2009 May; 69(8):1059-75. PubMed ID: 19496631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].
    Llibre JM; Martínez-Picado J
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():17-22. PubMed ID: 19572421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of raltegravir: from healthy volunteers to phase III trials].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():29-33. PubMed ID: 19572423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV resistance to raltegravir.
    Clavel F
    Eur J Med Res; 2009 Nov; 14 Suppl 3(Suppl 3):47-54. PubMed ID: 19959417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
    da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
    J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir as antiretroviral therapy in HIV/AIDS.
    Sharma M; Walmsley SL
    Expert Opin Pharmacother; 2014 Feb; 15(3):395-405. PubMed ID: 24304203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir: in treatment-naive patients with HIV-1 infection.
    Croxtall JD; Scott LJ
    Drugs; 2010 Mar; 70(5):631-42. PubMed ID: 20329808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the HIV integration process in antiviral therapy.
    McNeely M; Christ F; Thys W; Debyser Z
    J HIV Ther; 2008 Dec; 13(4):83-92. PubMed ID: 19418658
    [No Abstract]   [Full Text] [Related]  

  • 17. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
    Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [How proviral DNA is integrated into the host cell DNA and how this process can be inhibited].
    Mirambeau G
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():11-6. PubMed ID: 19572420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report from the 2008 joint ICAAC/IDSA meeting. More on raltegravir: resistance and mechanisms of action.
    Albrecht H
    AIDS Clin Care; 2008 Dec; 20(12):97-8. PubMed ID: 19274773
    [No Abstract]   [Full Text] [Related]  

  • 20. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.
    Delelis O; Malet I; Na L; Tchertanov L; Calvez V; Marcelin AG; Subra F; Deprez E; Mouscadet JF
    Nucleic Acids Res; 2009 Mar; 37(4):1193-201. PubMed ID: 19129221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.